Development and Preclinical Evaluation of Novel F-18-Labeled Dihydropyrazole RIPK1 PET Tracers for Neuroinflammation Imaging
- 21 November 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 25590-25606
Abstract
Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation and cell death, making it a promising target for diagnosing neurodegenerative diseases. In this study, we developed and evaluated two novel dihydropyrazole-based PET tracers, [18F]PB833 and [18F]PB830, through structural optimization of dihydropyrazole-based inhibitors. Both tracers demonstrated good blood-brain barrier penetration in rodents. Notably, [18F]PB830 showed superior brain uptake, binding specificity, and metabolic stability. In a mouse model of neuroinflammation, the [18F]PB830 PET signal was significantly elevated, which correlated with increased RIPK1 expression confirmed by immunofluorescence. Furthermore, [18F]PB830 showed robust brain uptake in nonhuman primates with a peak SUV of 2.6, indicating the translational potential. Our findings establish [18F]PB830 as a promising PET radioligand for noninvasive assessment of neuroinflammation and for preclinical studies of neurodegenerative diseases.Keywords
Funding Information
- West China Hospital, Sichuan University (137220092, ZYGD23016)
- Natural Science Foundation of Sichuan Province (25NSFSC2196)
- Science and Technology Department of Sichuan Province (2025ZNSFSC0657)
This publication has 46 references indexed in Scilit:
- Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's DiseaseAdvanced Science, 2024
- Synthesis and preclinical evaluation of 11C-labeled 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine radioligands for RIPK1 positron emission tomography imagingBioorganic Chemistry, 2024
- Ripks and NeuroinflammationMolecular Neurobiology, 2024
- RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug developmentEuropean Journal of Medicinal Chemistry, 2024
- Strategies for designing novel positron emission tomography (PET) radiotracers to cross the blood–brain barrierJournal of Labelled Compounds and Radiopharmaceuticals, 2023
- Potent and Selective RIPK1 Inhibitors Targeting Dual‐Pockets for the Treatment of Systemic Inflammatory Response Syndrome and SepsisAngewandte Chemie International Edition, 2021
- Radioligand development for molecular imaging of the central nervous system with positron emission tomographyDrug Discovery Today, 2014
- Positron emission tomography imaging in neurological disordersJournal of Neurology, 2012
- Challenges for Developing PET Tracers: Isotopes, Chemistry, and Regulatory AspectsPET Clinics, 2010
- Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced InflammationCell, 2009